Description
FOXO4-DRI – Senolytic & Cellular Regeneration Research Peptide
FOXO4-DRI 10 mg is a synthetic senolytic peptide designed to selectively target and induce apoptosis in senescent (aging) cells. Derived from the FOXO4 transcription factor, this D-retro-inverso analog disrupts the interaction between FOXO4 and p53, allowing the controlled removal of damaged, non-dividing cells while preserving healthy tissue.
FOXO4-DRI is widely studied for its potential in anti-aging, regenerative medicine, tissue rejuvenation, and cellular longevity research due to its unique mechanism that directly eliminates cellular senescence — a key driver of aging and degenerative decline.
Key Features & Research Applications
🧬 Senolytic Action:
Promotes apoptosis of senescent cells by inhibiting FOXO4–p53 binding, allowing cellular renewal.
🧠 Anti-Aging Research:
Studied for rejuvenation effects in aged tissues, improving vitality and regenerative capacity in preclinical models.
💪 Tissue Regeneration:
Supports restoration of normal cell turnover and regeneration in muscle, skin, and organ systems.
❤️ Cellular Health & Longevity:
Helps maintain youthful cellular populations and reduces inflammatory signaling associated with aging.
🔬 Disease & Degeneration Studies:
Applied in research on age-related diseases, cancer biology, fibrosis, and neurodegeneration.
Product Details
-
Name: FOXO4-DRI (D-Retro-Inverso Peptide)
-
Form: Lyophilized powder
-
Sequence: Ac–dRVRR–(varied FOXO4 domain)–NH₂ (D-retro-inverso configuration for stability)
-
Molecular Formula: C₃₈₆H₆₄₆N₁₀₈O₁₂₀S₂
-
Molecular Weight: ~8,900 Da
-
Purity: ≥ 98% (HPLC verified)
-
Dosage Strength: 10 mg per vial
-
Appearance: White to off-white lyophilized powder
-
Storage: Store in a cool, dry place; refrigerate 35.6–46.4°F) after reconstitution; avoid freeze–thaw cycles.
-
Packaging: Sterile, sealed research-grade vial
-
Verification: Third-party tested for purity and identity
